Aspira Women’s Health (NASDAQ:AWH) Releases Earnings Results, Beats Estimates By $0.04 EPS

Aspira Women’s Health (NASDAQ:AWH) announced its earnings results on Monday. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04, Yahoo Finance reports. The business had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same period in the previous year, the firm earned ($0.28) earnings per share.

Aspira Women’s Health Stock Performance

NASDAQ AWH traded up $0.10 on Wednesday, reaching $1.19. The company had a trading volume of 495,846 shares, compared to its average volume of 67,832. The company’s fifty day moving average is $1.45 and its 200-day moving average is $2.81. The firm has a market capitalization of $14.82 million, a price-to-earnings ratio of -0.91 and a beta of 1.54. Aspira Women’s Health has a 1-year low of $0.86 and a 1-year high of $6.75.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Aspira Women’s Health from a “sell” rating to a “hold” rating in a research note on Wednesday.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.